Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
It is our hypothesis that a course of Ta1 administered to hospitalized individuals with
COVID-19 infection and lymphocytopenia will improve the time to recovery (primary objective)
and severity of infection (secondary objectives) compared to untreated individuals in the
same hospital with comparable lymphocytopenia.
After screening, hospitalized patients with COVID-19 and lymphocytopenia who meet the
inclusion criteria will receive Ta1 (1.6 mg) administered subcutaneously (SC) daily for 1
week. Individuals in the control arm will be followed on the identical protocol but will not
receive daily Ta1.